BIRC5 and glioblastoma: Pharmacotherapeutics well studied in non-nervous system pathologies, including the anti-malarial agent Artesunate, intriguingly show promise for radio-sensitizing glioblastoma cells through possible downregulation of survivin by unknown mechanisms [87,88].